Down 99%, biotech firm 180 Life Sciences pivots to crypto with ETH bet

The Nasdaq-listed biotechnology firm is raising $425 million for its ETH strategy, joining a parade of penny stocks investing in cryptocurrencies as their business flounders.

Related Posts

Leave a Reply

Recent Articles

Hyperliquid now allows anyone to deploy perpetual futures — for a price
October 14, 2025
Binance Wallet, Trust Wallet display issues linger after crypto crash
October 14, 2025
Bitcoin mining stocks rebound after Trump’s tariff threat sparked market turmoil
October 14, 2025

Text Widget

Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.

Post Category